carmustine has been researched along with Pituitary Neoplasms in 4 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment." | 3.88 | Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. ( Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J, 2018) |
| "Ten patients, nine with pituitary adenomas and one with a craniopharyngioma, underwent implantation of from two to eight Gliadel wafers." | 2.71 | Gliadel for pituitary adenomas and craniopharyngiomas. ( Laws, ER; Maartens, N; Morris, AM, 2003) |
| "Forty-three patients with brain tumors were entered into the study." | 1.29 | Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. ( Kowada, M; Mineura, K; Watanabe, K; Yanagisawa, T; Yasui, N, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McCormack, A | 1 |
| Dekkers, OM | 1 |
| Petersenn, S | 1 |
| Popovic, V | 1 |
| Trouillas, J | 1 |
| Raverot, G | 1 |
| Burman, P | 1 |
| Laws, ER | 1 |
| Morris, AM | 1 |
| Maartens, N | 1 |
| LOW-BEER, BV | 1 |
| SCOFIELD, NE | 1 |
| FELDSTED, ET | 1 |
| BROWN, RF | 1 |
| Mineura, K | 1 |
| Yanagisawa, T | 1 |
| Watanabe, K | 1 |
| Kowada, M | 1 |
| Yasui, N | 1 |
1 trial available for carmustine and Pituitary Neoplasms
| Article | Year |
|---|---|
Gliadel for pituitary adenomas and craniopharyngiomas.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Craniopharyngioma; Drug Carrier | 2003 |
3 other studies available for carmustine and Pituitary Neoplasms
| Article | Year |
|---|---|
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2018 |
Directed beam therapy. II. Multiple small field irradiation of the pituitary gland, pituitary tumors and other intracranial lesions.
Topics: Carmustine; Humans; Pituitary Gland; Pituitary Neoplasms; Radiotherapy | 1953 |
Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Carmustine; DNA Repair; Glioma; Huma | 1996 |